^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT142

    i
    Associations
    News

    Trials

    Company:
    BioNTech
    Drug class:
    CD3 agonist, CLDN6 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety and Preliminary Efficacy Trial of BNT142 in Patients with CLDN6-positive Solid Tumors (NCT05262530)
    Phase 1/2
    BioNTech SE
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/28/2022
    Primary completion :
    10/01/2025
    Completion :
    04/01/2026
    CLDN6
    |
    CLDN6 positive
    |
    BNT142